Ana Rita Lima1, Joana Pinto2, Maria de Lourdes Bastos2, Márcia Carvalho2,3, Paula Guedes de Pinho4. 1. UCIBIO/REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313, Porto, Portugal. ritacmlima@hotmail.com. 2. UCIBIO/REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313, Porto, Portugal. 3. UFP Energy, Environment and Health Research Unit (FP-ENAS), University Fernando Pessoa, Porto, Portugal. 4. UCIBIO/REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313, Porto, Portugal. pguedes@ff.up.pt.
Abstract
INTRODUCTION: Prostate cancer (PCa) is one of the most prevalent cancers in men worldwide. Serum prostate-specific antigen (PSA) remains the most used biomarker in the detection and management of patients with PCa, in spite of the problems related with its low specificity, false positive rate and overdiagnosis. Furthermore, PSA is unable to discriminate indolent from aggressive PCa, which can lead to overtreatment. Early diagnosed and treated PCa can have a good prognosis and is potentially curable. Therefore, the discovery of new biomarkers able to detect clinically significant aggressive PCa is urgently needed. METHODS: This revision was based on an electronic literature search, using Pubmed, with Nuclear Magnetic Resonance (NMR), tissue and prostate cancer as keywords. All metabolomic studies performed in PCa tissues by NMR spectroscopy, from 2007 until March 2018, were included in this review. RESULTS: In the context of cancer, metabolomics allows the analysis of the entire metabolic profile of cancer cells. Several metabolic alterations occur in cancer cells to sustain their abnormal rates of proliferation. NMR proved to be a suitable methodology for the evaluation of these metabolic alterations in PCa tissues, allowing to unveil alterations in citrate, spermine, choline, choline-related compounds, lactate, alanine and glutamate. CONCLUSION: The study of the metabolic alterations associated with PCa progression, accomplished by the analysis of PCa tissue by NMR, offers a promising approach for elucidating biochemical pathways affected by PCa and also for discovering new clinical biomarkers. The main metabolomic alterations associated with PCa development and promising biomarker metabolites for diagnosis of PCa were outlined.
INTRODUCTION:Prostate cancer (PCa) is one of the most prevalent cancers in men worldwide. Serum prostate-specific antigen (PSA) remains the most used biomarker in the detection and management of patients with PCa, in spite of the problems related with its low specificity, false positive rate and overdiagnosis. Furthermore, PSA is unable to discriminate indolent from aggressive PCa, which can lead to overtreatment. Early diagnosed and treated PCa can have a good prognosis and is potentially curable. Therefore, the discovery of new biomarkers able to detect clinically significant aggressive PCa is urgently needed. METHODS: This revision was based on an electronic literature search, using Pubmed, with Nuclear Magnetic Resonance (NMR), tissue and prostate cancer as keywords. All metabolomic studies performed in PCa tissues by NMR spectroscopy, from 2007 until March 2018, were included in this review. RESULTS: In the context of cancer, metabolomics allows the analysis of the entire metabolic profile of cancer cells. Several metabolic alterations occur in cancer cells to sustain their abnormal rates of proliferation. NMR proved to be a suitable methodology for the evaluation of these metabolic alterations in PCa tissues, allowing to unveil alterations in citrate, spermine, choline, choline-related compounds, lactate, alanine and glutamate. CONCLUSION: The study of the metabolic alterations associated with PCa progression, accomplished by the analysis of PCa tissue by NMR, offers a promising approach for elucidating biochemical pathways affected by PCa and also for discovering new clinical biomarkers. The main metabolomic alterations associated with PCa development and promising biomarker metabolites for diagnosis of PCa were outlined.
Entities:
Keywords:
Metabolomics; Nuclear magnetic resonance spectroscopy; Prostate cancer; Tissues
Authors: R Dittrich; J Kurth; E A Decelle; E M DeFeo; M Taupitz; S Wu; C-L Wu; W S McDougal; L L Cheng Journal: Prostate Cancer Prostatic Dis Date: 2012-01-31 Impact factor: 5.554
Authors: Kari Rostad; Olaf J C Hellwinkel; Svein A Haukaas; Ole J Halvorsen; Anne M Øyan; Alexander Haese; Lars Budäus; Heiko Albrecht; Lars A Akslen; Thorsten Schlomm; Karl-Henning Kalland Journal: APMIS Date: 2009-08 Impact factor: 3.205
Authors: Caroline E Nunes-Xavier; Janire Mingo; Maite Emaldi; Karine Flem-Karlsen; Gunhild M Mælandsmo; Øystein Fodstad; Roberto Llarena; José I López; Rafael Pulido Journal: Front Oncol Date: 2022-05-25 Impact factor: 5.738
Authors: Annabel Steiner; Stefan Andreas Schmidt; Cara Sophie Fellmann; Johannes Nowak; Chin-Lee Wu; Adam Scott Feldman; Meinrad Beer; Leo L Cheng Journal: Cancers (Basel) Date: 2022-04-26 Impact factor: 6.575
Authors: Ana Rita Lima; Joana Pinto; Filipa Amaro; Maria de Lourdes Bastos; Márcia Carvalho; Paula Guedes de Pinho Journal: Metabolites Date: 2021-03-19